February 3, 2022
The MMA’s next noon-time forum will examine sodium-glucose cotransporter-2 (SGLT2) inhibitors, a new 'triple play' for diabetes, cardiovascular and kidney diseases. The forum will take place February 9 from noon to 1 p.m.
This forum will review the pharmacology of SGLT2 inhibitors and then discuss the role these drugs play in the management of type 2 diabetes. The evidence for improving cardiorenal outcomes will be presented and recommendations made for the use of these drugs in patients with cardiovascular or renal diseases. The session will conclude with a Q&A panel discussion.
The forum will be moderated by Andrew Olson, MD, and include Anne Bantle, MD, Prabhjot S. Nijjar, MD, and Mark Rosenberg, MD. All faculty for this forum are with the University of Minnesota Medical School.
Learning objectives for the forum include:
Describe the pharmacology of SGLT2 inhibitors and the use of these drugs in the management of type 2 diabetes mellitus.
Appraise the data supporting the cardiorenal protective effects of SGLT2 inhibitors.
Utilize SGLT2 inhibitors in the management of patients with diabetes, cardiovascular or kidney diseases.
To register, click here.
The forum is free to members, $15 for non-members. This forum is being held in partnership with the University of Minnesota.
April 9, 2026
An amended piece of legislation that would exempt buprenorphine from prior authorization (PA) was heard in the Senate Health and Human Services Committee on April 9.
April 9, 2026
On April 9, the Senate Health and Human Services Committee heard a bill that would require coverage for psychiatric Collaborative Care Model (CoCM) services under Medical Assistance.
April 9, 2026
On April 9, the House Taxes Committee heard legislation focused on supporting the financial stability and ongoing operations of Hennepin Healthcare.